---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-011545"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:41:52.009457+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biofrontera reports record Q4 revenue $17.1M, net income $5.6M; full-year 2025 revenue up 12% to $41.7M

## Summary
- Q4 2025 revenue $17.1M, up 36% YoY; net income $5.6M vs. net loss $1.4M in Q4 2024.
- Full-year 2025 revenue $41.7M, up 12% YoY; net loss narrowed to $10.5M from $17.7M.
- Gross margin improved to 82.4% in Q4 (from 58.0%) due to new earnout structure after asset purchase from Biofrontera AG.
- Adjusted EBITDA was $4.9M in Q4 vs. -$1.4M; full-year Adjusted EBITDA -$10.6M vs. -$15.3M.
- Pipeline: PDUFA date for sBCC September 2026; positive Phase 3 AK results; Phase 2b acne data.

## SEC filing metadata
- accession: 0001493152-26-011545
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315226011545/0001493152-26-011545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315226011545/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-011545
- JSON: https://secwatch.observer/filing/0001493152-26-011545.json
- Plain text: https://secwatch.observer/filing/0001493152-26-011545.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.